Viking Therapeutics and the Next Wave of GLP-1 Competitors
Viking Therapeutics is among several smaller biopharma companies with GLP-1 or dual-agonist candidates in clinical trials, aiming at the same weight-management market as Novo Nordisk and Eli Lilly.
By the GLP Semaglutide editorial team · Last updated May 8, 2026
Viking Therapeutics has been developing VK2735, a dual GLP-1/GIP receptor agonist studied in both injectable and oral formulations, positioning it as a potential competitor to Novo Nordisk's and Eli Lilly's approved GLP-1 drugs.
Early trials aren't approval
Positive early or mid-stage trial results generate significant market attention but are not the same as FDA approval, which requires larger late-stage trials and a full regulatory review that can take years and isn't guaranteed to succeed.
Where to track progress
Company press releases and ClinicalTrials.gov listings are the most current primary sources for trial phase and status; competitive dynamics in this space shift quickly as trial data reads out.
Primary sources